Co-Diagnostics Debt to Equity Ratio 2017-2025 | CODX
Current and historical debt to equity ratio values for Co-Diagnostics (CODX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Co-Diagnostics debt/equity for the three months ending March 31, 2025 was 0.00.
| Co-Diagnostics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.01B | $0.05B | 0.15 |
| 2024-12-31 | $0.01B | $0.05B | 0.18 |
| 2024-09-30 | $0.01B | $0.06B | 0.14 |
| 2024-06-30 | $0.01B | $0.07B | 0.12 |
| 2024-03-31 | $0.01B | $0.08B | 0.11 |
| 2023-12-31 | $0.01B | $0.09B | 0.11 |
| 2023-09-30 | $0.01B | $0.10B | 0.09 |
| 2023-06-30 | $0.01B | $0.10B | 0.09 |
| 2023-03-31 | $0.01B | $0.11B | 0.06 |
| 2022-12-31 | $0.01B | $0.12B | 0.08 |
| 2022-09-30 | $0.01B | $0.14B | 0.10 |
| 2022-06-30 | $0.02B | $0.14B | 0.11 |
| 2022-03-31 | $0.02B | $0.15B | 0.16 |
| 2021-12-31 | $0.03B | $0.13B | 0.19 |
| 2021-09-30 | $0.01B | $0.10B | 0.05 |
| 2021-06-30 | $0.01B | $0.09B | 0.06 |
| 2021-03-31 | $0.01B | $0.08B | 0.06 |
| 2020-12-31 | $0.01B | $0.07B | 0.07 |
| 2020-09-30 | $0.00B | $0.05B | 0.04 |
| 2020-06-30 | $0.00B | $0.04B | 0.09 |
| 2020-03-31 | $0.00B | $0.02B | 0.07 |
| 2019-12-31 | $0.00B | $0.00B | 0.28 |
| 2019-09-30 | $0.00B | $0.00B | 0.14 |
| 2019-06-30 | $0.00B | $0.01B | 0.11 |
| 2019-03-31 | $0.00B | $0.01B | 0.10 |
| 2018-12-31 | $0.00B | $0.00B | -2.47 |
| 2018-09-30 | $0.00B | $0.00B | 20.30 |
| 2018-06-30 | $0.00B | $0.00B | 0.58 |
| 2018-03-31 | $0.00B | $0.00B | 0.30 |
| 2017-12-31 | $0.00B | $0.00B | 0.21 |
| 2017-09-30 | $0.00B | $0.01B | 0.17 |
| 2017-06-30 | $0.01B | $0.00B | -1.11 |
| 2017-03-31 | $0.00B | $0.00B | 0.00 |
| 2016-12-31 | $0.00B | 0.00 | |
| 2016-09-30 | $0.00B | $0.00B | 0.00 |
| 2016-06-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.009B | $0.004B |
| Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics Inc. is based in UT, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $135.906B | 25.49 |
| Elevance Health (ELV) | United States | $86.723B | 11.19 |
| CVS Health (CVS) | United States | $81.012B | 10.07 |
| Cencora (COR) | United States | $56.449B | 19.64 |
| DiDi Global (DIDIY) | China | $21.556B | 32.71 |
| Natera (NTRA) | United States | $21.537B | 0.00 |
| BioMerieux (BMXMF) | France | $15.890B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.928B | 0.00 |
| Solventum (SOLV) | United States | $12.646B | 13.39 |
| CochLear (CHEOY) | Australia | $11.378B | 0.00 |
| Revvity (RVTY) | United States | $10.658B | 18.34 |
| ICON (ICLR) | Ireland | $10.521B | 9.78 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Doximity (DOCS) | United States | $9.784B | 45.30 |
| Avantor (AVTR) | United States | $8.797B | 12.78 |
| HealthEquity (HQY) | United States | $8.702B | 42.81 |
| Medpace Holdings (MEDP) | United States | $8.476B | 22.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.311B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.662B | 13.05 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 27.18 |
| BrightSpring Health Services (BTSG) | United States | $4.149B | 38.40 |
| Bausch + Lomb (BLCO) | Canada | $4.054B | 23.90 |
| Sotera Health (SHC) | United States | $3.474B | 19.74 |
| Alignment Healthcare (ALHC) | United States | $3.041B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.026B | 39.35 |
| Concentras Parent (CON) | United States | $2.772B | 16.02 |
| Organon (OGN) | United States | $2.397B | 2.55 |
| Ardent Health Partners (ARDT) | United States | $2.071B | 8.83 |
| GeneDx Holdings (WGS) | United States | $2.032B | 78.26 |
| Premier (PINC) | United States | $1.892B | 14.36 |
| Progyny (PGNY) | United States | $1.843B | 40.57 |
| PACS (PACS) | United States | $1.512B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.400B | 28.00 |
| Pediatrix Medical (MD) | United States | $1.216B | 9.25 |
| Teladoc Health (TDOC) | United States | $1.214B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.995B | 0.00 | |
| CareDx (CDNA) | United States | $0.946B | 14.77 |
| Nutex Health (NUTX) | United States | $0.934B | 14.11 |
| Agilon Health (AGL) | United States | $0.919B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.808B | 7.57 |
| Embecta (EMBC) | United States | $0.615B | 4.15 |
| LifeMD (LFMD) | United States | $0.555B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.552B | 0.00 |
| Enhabit (EHAB) | United States | $0.532B | 43.75 |
| SBC Medicals (SBC) | United States | $0.532B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.474B | 10.67 |
| Sonida Senior Living (SNDA) | United States | $0.460B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.389B | 0.00 |
| Oncology Institute (TOI) | United States | $0.285B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.240B | 0.00 |
| Beauty Health (SKIN) | United States | $0.205B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| KindlyMD (NAKA) | United States | $0.136B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.112B | 0.00 |
| OncoCyte (OCX) | United States | $0.095B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.067B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.058B | 0.00 |
| Biodesix (BDSX) | United States | $0.044B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| ModivCare (MODV) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |